Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this trial is to evaluate changes in cardiac iron as measured by MRI T2* in beta-thalassemia patients with deferasirox treatment.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| deferasirox every day for 77 weeks | Experimental | Participants received Deferasirox 30 milligrams per kilogram per day (mg/kg/day) orally once daily (OD), 30 minutes before breakfast, preferably around the same time every morning if possible. Deferasirox tablets were dropped into water or orange juice, or apple juice and stirred until completely dispersed. For doses less than 1 gram (g), tablets were dissolved in at least 100 milliliter (mL) of liquid; for doses of 1 to 3 g, tablets were dissolved in at least 200 mL. After tablets were fully disintegrated, the liquid was promptly consumed. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Deferasirox | Drug | Oral deferasirox 30mg/kg/day once per day for 77 weeks. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Magnetic Resonance Imaging (MRI) T2* and Absolute Change From Baseline in MRI T2* | Cardiac T2* was measured in the short axis plane at the widest point of a 4-chamber localizer using custom breath-hold R2* gradient echo sequences modeled after techniques used by Anderson et al (2001) and Westwood et al (2003). | From Baseline to 25, 49, 77 Week |
| Measure | Description | Time Frame |
|---|---|---|
| Change From Baseline in Liver Iron Concentration (LIC) Was Measured by MRI R2 From Absolute Change From Baseline to 101 Weeks | MRI evaluation of liver iron concentration has been validated by liver biopsy (St Pierre et al 2005). Studies comparing T2* values of liver iron concentration (LIC) with LIC as assessed by biopsy have confirmed that T2* values reflect liver iron content (Wood et al 2003b). Direct tissue-validation of cardiac T2* measurements in humans has not been performed because endomyocardial biopsy is a dangerous and unreliable indicator of cardiac iron overload (Olson et al 1989, Fitchett et al 1980). However, it has been shown that cardiac T2* accurately reflects cardiac iron in a gerbil iron cardiomyopathy model (Wood et al 2004b). T2* measurements have shown excellent inter-scanner and inter-exam reproducibility, making them suitable for longitudinal monitoring (Westwood et al 2003a, Westwood et al 2003b). |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Thomas Coates, MD | Childresn's Hospital of Los Angeles | Principal Investigator |
| Alexis Thompson, MD | Children's Memorial Hospital of Chicago | Principal Investigator |
| Paul Harmatz, MD | Children's Hospital and Research Center at Oakland | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Childrens Hospital of Los Angeles | Los Angeles | California | 90027 | United States | ||
| Children's Hospital and Research Center at Oakland |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 21393329 | Derived | Wood JC, Glynos T, Thompson A, Giardina P, Harmatz P, Kang BP, Paley C, Coates TD. Relationship between labile plasma iron, liver iron concentration and cardiac response in a deferasirox monotherapy trial. Haematologica. 2011 Jul;96(7):1055-8. doi: 10.3324/haematol.2010.032862. Epub 2011 Mar 10. | |
| 20421452 | Derived |
| Label | URL |
|---|---|
| Novartis Clinical Trial results website | View source |
Not provided
A total number of participants planned for this study was 30. The total number of 28 participants enrolled in the study, of these 22 completed the study and 6 discontinued the study.
The study was conducted at 4 centers in the United States
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Deferasirox | Participants received Deferasirox 30 milligrams per kilogram per day (mg/kg/day) orally once daily (OD), 30 minutes before breakfast, preferably around the same time every morning if possible. Deferasirox tablets were dropped into water or orange juice, or apple juice and stirred until completely dispersed. For doses less than 1 gram (g), tablets were dissolved in at least 100 milliliter (mL) of liquid; for doses of 1 to 3 g, tablets were dissolved in at least 200 mL. After tablets were fully disintegrated, the liquid was promptly consumed. |
| Title | Milestones | Reasons Not Completed | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
The analysis was performed in Intent-to-treat (ITT) population, defined as all enrolled participants who received at least 1 dose of study drug and had at least 1 post-baseline assessment.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Deferasirox | Participants received Deferasirox 30 mg/kg/day orally OD, 30 minutes before breakfast, preferably around the same time every morning if possible. Deferasirox tablets were dropped into water or orange juice, or apple juice and stirred until completely dispersed. For doses less than 1 g, tablets were dissolved in at least 100 mL of liquid; for doses of 1 to 3 g, tablets were dissolved in at least 200 mL. After tablets were fully disintegrated, the liquid was promptly consumed. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Magnetic Resonance Imaging (MRI) T2* and Absolute Change From Baseline in MRI T2* | Cardiac T2* was measured in the short axis plane at the widest point of a 4-chamber localizer using custom breath-hold R2* gradient echo sequences modeled after techniques used by Anderson et al (2001) and Westwood et al (2003). | The analysis was performed in Completer population (CP) consists of those participants who had a Week 77 MRI. | Posted | Mean | Standard Deviation | milliseconds (msec) | From Baseline to 25, 49, 77 Week |
|
Adverse events are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All adverse events reported in this record are from date of First Patient First Treatment until Last Patient Last Visit (LPLV) up to week 77.
The analysis was performed on safety set population defined as all participants who received study drug and had at least one post-baseline safety assessment.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | All Patients | Participants received Deferasirox 30 mg/kg/day orally OD, 30 minutes before breakfast, preferably around the same time every morning if possible. Deferasirox tablets were dropped into water or orange juice, or apple juice and stirred until completely dispersed. For doses less than 1 g, tablets were dissolved in at least 100 mL of liquid; for doses of 1 to 3 g, tablets were dissolved in at least 200 mL. After tablets were fully disintegrated, the liquid was promptly consumed. |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Disseminated intravascular coagulation | Blood and lymphatic system disorders | MedDRA (12.0) | Systematic Assessment |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Left atrial dilatation | Cardiac disorders | MedDRA (12.0) | Systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Study Director | Novartis Pharmaceuticals | 862-778-8300 | Novartis.email@novartis.com |
Not provided
| ID | Term |
|---|---|
| D017086 | beta-Thalassemia |
| D019190 | Iron Overload |
| ID | Term |
|---|---|
| D013789 | Thalassemia |
| D000745 | Anemia, Hemolytic, Congenital |
| D000743 | Anemia, Hemolytic |
| D000740 | Anemia |
Not provided
Not provided
| ID | Term |
|---|---|
| D000077588 | Deferasirox |
| ID | Term |
|---|---|
| D001565 | Benzoates |
| D000146 | Acids, Carbocyclic |
| D002264 | Carboxylic Acids |
| D009930 | Organic Chemicals |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| From Baseline to 25, 49, 77 Week |
| Left Ventricular Ejection Fraction (LVEF) and Change in Left Ventricular Ejection Fraction From Baseline to 101 Weeks | Magnetic resonance imaging (MRI)-measured cardiac T2* and cardiac function reflected by left and right ventricle ejection fraction. A standardized MRI protocol for T2* acquisition technique will be used in the centers. Images will be reviewed centrally by an expert MRI reader. | From Baseline to 25, 49, 77 Week |
| Serum Ferritin and Changes From Baseline in Serum Ferritin During Study | Serum ferritin will be assessed at each study visit. Analysis was performed in Completer population consists of those participants who had a Week 77 MRI. | From Baseline to 25, 49, 77 Week |
| Oakland |
| California |
| 94609 |
| United States |
| Children's Memorial Hospital | Chicago | Illinois | 60614 | United States |
| Wood JC, Kang BP, Thompson A, Giardina P, Harmatz P, Glynos T, Paley C, Coates TD. The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores. Blood. 2010 Jul 29;116(4):537-43. doi: 10.1182/blood-2009-11-250308. Epub 2010 Apr 26. |
| Withdrawal by Subject |
|
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race/Ethnicity, Customized | Number | participants |
|
|
|
| Secondary | Change From Baseline in Liver Iron Concentration (LIC) Was Measured by MRI R2 From Absolute Change From Baseline to 101 Weeks | MRI evaluation of liver iron concentration has been validated by liver biopsy (St Pierre et al 2005). Studies comparing T2* values of liver iron concentration (LIC) with LIC as assessed by biopsy have confirmed that T2* values reflect liver iron content (Wood et al 2003b). Direct tissue-validation of cardiac T2* measurements in humans has not been performed because endomyocardial biopsy is a dangerous and unreliable indicator of cardiac iron overload (Olson et al 1989, Fitchett et al 1980). However, it has been shown that cardiac T2* accurately reflects cardiac iron in a gerbil iron cardiomyopathy model (Wood et al 2004b). T2* measurements have shown excellent inter-scanner and inter-exam reproducibility, making them suitable for longitudinal monitoring (Westwood et al 2003a, Westwood et al 2003b). | The analysis was performed in Completer population consists of those participants who had a Week 77 MRI. | Posted | Mean | Standard Deviation | mg Fe/g dw liver | From Baseline to 25, 49, 77 Week |
|
|
|
| Secondary | Left Ventricular Ejection Fraction (LVEF) and Change in Left Ventricular Ejection Fraction From Baseline to 101 Weeks | Magnetic resonance imaging (MRI)-measured cardiac T2* and cardiac function reflected by left and right ventricle ejection fraction. A standardized MRI protocol for T2* acquisition technique will be used in the centers. Images will be reviewed centrally by an expert MRI reader. | The analysis was performed in Completer population consisting of those participants who had a Week 77 MRI. | Posted | Mean | Standard Deviation | percentage of participants | From Baseline to 25, 49, 77 Week |
|
|
|
| Secondary | Serum Ferritin and Changes From Baseline in Serum Ferritin During Study | Serum ferritin will be assessed at each study visit. Analysis was performed in Completer population consists of those participants who had a Week 77 MRI. | The analysis was performed in Completer population consists of those participants who had a Week 77 MRI. | Posted | Mean | Standard Deviation | μg/L | From Baseline to 25, 49, 77 Week |
|
|
|
| 0 |
| 27 |
| 8 |
| 27 |
| 27 |
| 27 |
| Thrombocytopenia | Blood and lymphatic system disorders | MedDRA (12.0) | Systematic Assessment |
|
| Arrhythmia | Cardiac disorders | MedDRA (12.0) | Systematic Assessment |
|
| Cardiac failure | Cardiac disorders | MedDRA (12.0) | Systematic Assessment |
|
| Tachycardia | Cardiac disorders | MedDRA (12.0) | Systematic Assessment |
|
| Fanconi syndrome | Congenital, familial and genetic disorders | MedDRA (12.0) | Systematic Assessment |
|
| Abdominal compartment syndrome | Gastrointestinal disorders | MedDRA (12.0) | Systematic Assessment |
|
| Abdominal pain | Gastrointestinal disorders | MedDRA (12.0) | Systematic Assessment |
|
| Ascites | Gastrointestinal disorders | MedDRA (12.0) | Systematic Assessment |
|
| Colitis | Gastrointestinal disorders | MedDRA (12.0) | Systematic Assessment |
|
| Gastrointestinal oedema | Gastrointestinal disorders | MedDRA (12.0) | Systematic Assessment |
|
| Nausea | Gastrointestinal disorders | MedDRA (12.0) | Systematic Assessment |
|
| Pancreatitis | Gastrointestinal disorders | MedDRA (12.0) | Systematic Assessment |
|
| Vomiting | Gastrointestinal disorders | MedDRA (12.0) | Systematic Assessment |
|
| Multi-organ failure | General disorders | MedDRA (12.0) | Systematic Assessment |
|
| Pyrexia | General disorders | MedDRA (12.0) | Systematic Assessment |
|
| Hepatic failure | Hepatobiliary disorders | MedDRA (12.0) | Systematic Assessment |
|
| Hepatic steatosis | Hepatobiliary disorders | MedDRA (12.0) | Systematic Assessment |
|
| Hepatitis | Hepatobiliary disorders | MedDRA (12.0) | Systematic Assessment |
|
| Aspergillosis | Infections and infestations | MedDRA (12.0) | Systematic Assessment |
|
| Bacterial infection | Infections and infestations | MedDRA (12.0) | Systematic Assessment |
|
| Bronchitis viral | Infections and infestations | MedDRA (12.0) | Systematic Assessment |
|
| Herpes simplex | Infections and infestations | MedDRA (12.0) | Systematic Assessment |
|
| Pneumonia | Infections and infestations | MedDRA (12.0) | Systematic Assessment |
|
| Sepsis | Infections and infestations | MedDRA (12.0) | Systematic Assessment |
|
| Septic shock | Infections and infestations | MedDRA (12.0) | Systematic Assessment |
|
| Urinary tract infection | Infections and infestations | MedDRA (12.0) | Systematic Assessment |
|
| Urinary tract infection fungal | Infections and infestations | MedDRA (12.0) | Systematic Assessment |
|
| Fibula fracture | Injury, poisoning and procedural complications | MedDRA (12.0) | Systematic Assessment |
|
| Splenic rupture | Injury, poisoning and procedural complications | MedDRA (12.0) | Systematic Assessment |
|
| Tibia fracture | Injury, poisoning and procedural complications | MedDRA (12.0) | Systematic Assessment |
|
| Blood creatinine increased | Investigations | MedDRA (12.0) | Systematic Assessment |
|
| Blood phosphorus decreased | Investigations | MedDRA (12.0) | Systematic Assessment |
|
| Ejection fraction decreased | Investigations | MedDRA (12.0) | Systematic Assessment |
|
| Urine analysis abnormal | Investigations | MedDRA (12.0) | Systematic Assessment |
|
| Acidosis | Metabolism and nutrition disorders | MedDRA (12.0) | Systematic Assessment |
|
| Acidosis hyperchloraemic | Metabolism and nutrition disorders | MedDRA (12.0) | Systematic Assessment |
|
| Anorexia | Metabolism and nutrition disorders | MedDRA (12.0) | Systematic Assessment |
|
| Dehydration | Metabolism and nutrition disorders | MedDRA (12.0) | Systematic Assessment |
|
| Hyperglycaemia | Metabolism and nutrition disorders | MedDRA (12.0) | Systematic Assessment |
|
| Back pain | Musculoskeletal and connective tissue disorders | MedDRA (12.0) | Systematic Assessment |
|
| Depressed level of consciousness | Nervous system disorders | MedDRA (12.0) | Systematic Assessment |
|
| Unresponsive to stimuli | Nervous system disorders | MedDRA (12.0) | Systematic Assessment |
|
| Mental status changes | Psychiatric disorders | MedDRA (12.0) | Systematic Assessment |
|
| Psychotic disorder | Psychiatric disorders | MedDRA (12.0) | Systematic Assessment |
|
| Azotaemia | Renal and urinary disorders | MedDRA (12.0) | Systematic Assessment |
|
| Polyuria | Renal and urinary disorders | MedDRA (12.0) | Systematic Assessment |
|
| Renal failure | Renal and urinary disorders | MedDRA (12.0) | Systematic Assessment |
|
| Pharyngolaryngeal pain | Respiratory, thoracic and mediastinal disorders | MedDRA (12.0) | Systematic Assessment |
|
| Pulmonary oedema | Respiratory, thoracic and mediastinal disorders | MedDRA (12.0) | Systematic Assessment |
|
| Respiratory failure | Respiratory, thoracic and mediastinal disorders | MedDRA (12.0) | Systematic Assessment |
|
| Hypoperfusion | Vascular disorders | MedDRA (12.0) | Systematic Assessment |
|
| Hypotension | Vascular disorders | MedDRA (12.0) | Systematic Assessment |
|
| Shock | Vascular disorders | MedDRA (12.0) | Systematic Assessment |
|
| Left ventricular hypertrophy | Cardiac disorders | MedDRA (12.0) | Systematic Assessment |
|
| Sinus bradycardia | Cardiac disorders | MedDRA (12.0) | Systematic Assessment |
|
| Sinus tachycardia | Cardiac disorders | MedDRA (12.0) | Systematic Assessment |
|
| Tachycardia | Cardiac disorders | MedDRA (12.0) | Systematic Assessment |
|
| Vertigo | Ear and labyrinth disorders | MedDRA (12.0) | Systematic Assessment |
|
| Conjunctivitis | Eye disorders | MedDRA (12.0) | Systematic Assessment |
|
| Conjunctivitis allergic | Eye disorders | MedDRA (12.0) | Systematic Assessment |
|
| Dry eye | Eye disorders | MedDRA (12.0) | Systematic Assessment |
|
| Eye irritation | Eye disorders | MedDRA (12.0) | Systematic Assessment |
|
| Abdominal pain | Gastrointestinal disorders | MedDRA (12.0) | Systematic Assessment |
|
| Abdominal pain lower | Gastrointestinal disorders | MedDRA (12.0) | Systematic Assessment |
|
| Constipation | Gastrointestinal disorders | MedDRA (12.0) | Systematic Assessment |
|
| Diarrhoea | Gastrointestinal disorders | MedDRA (12.0) | Systematic Assessment |
|
| Dyspepsia | Gastrointestinal disorders | MedDRA (12.0) | Systematic Assessment |
|
| Gastritis | Gastrointestinal disorders | MedDRA (12.0) | Systematic Assessment |
|
| Nausea | Gastrointestinal disorders | MedDRA (12.0) | Systematic Assessment |
|
| Vomiting | Gastrointestinal disorders | MedDRA (12.0) | Systematic Assessment |
|
| Chest discomfort | General disorders | MedDRA (12.0) | Systematic Assessment |
|
| Chills | General disorders | MedDRA (12.0) | Systematic Assessment |
|
| Fatigue | General disorders | MedDRA (12.0) | Systematic Assessment |
|
| Non-cardiac chest pain | General disorders | MedDRA (12.0) | Systematic Assessment |
|
| Oedema | General disorders | MedDRA (12.0) | Systematic Assessment |
|
| Oedema peripheral | General disorders | MedDRA (12.0) | Systematic Assessment |
|
| Pain | General disorders | MedDRA (12.0) | Systematic Assessment |
|
| Pyrexia | General disorders | MedDRA (12.0) | Systematic Assessment |
|
| Cholelithiasis | Hepatobiliary disorders | MedDRA (12.0) | Systematic Assessment |
|
| House dust allergy | Immune system disorders | MedDRA (12.0) | Systematic Assessment |
|
| Candidiasis | Infections and infestations | MedDRA (12.0) | Systematic Assessment |
|
| Ear infection | Infections and infestations | MedDRA (12.0) | Systematic Assessment |
|
| Folliculitis | Infections and infestations | MedDRA (12.0) | Systematic Assessment |
|
| Fungal infection | Infections and infestations | MedDRA (12.0) | Systematic Assessment |
|
| Hordeolum | Infections and infestations | MedDRA (12.0) | Systematic Assessment |
|
| Nasopharyngitis | Infections and infestations | MedDRA (12.0) | Systematic Assessment |
|
| Oral herpes | Infections and infestations | MedDRA (12.0) | Systematic Assessment |
|
| Pharyngitis | Infections and infestations | MedDRA (12.0) | Systematic Assessment |
|
| Sinusitis | Infections and infestations | MedDRA (12.0) | Systematic Assessment |
|
| Upper respiratory tract infection | Infections and infestations | MedDRA (12.0) | Systematic Assessment |
|
| Urinary tract infection | Infections and infestations | MedDRA (12.0) | Systematic Assessment |
|
| Vulvovaginal mycotic infection | Infections and infestations | MedDRA (12.0) | Systematic Assessment |
|
| Animal bite | Injury, poisoning and procedural complications | MedDRA (12.0) | Systematic Assessment |
|
| Arthropod bite | Injury, poisoning and procedural complications | MedDRA (12.0) | Systematic Assessment |
|
| Arthropod sting | Injury, poisoning and procedural complications | MedDRA (12.0) | Systematic Assessment |
|
| Clavicle fracture | Injury, poisoning and procedural complications | MedDRA (12.0) | Systematic Assessment |
|
| Contusion | Injury, poisoning and procedural complications | MedDRA (12.0) | Systematic Assessment |
|
| Excoriation | Injury, poisoning and procedural complications | MedDRA (12.0) | Systematic Assessment |
|
| Joint injury | Injury, poisoning and procedural complications | MedDRA (12.0) | Systematic Assessment |
|
| Thoracic vertebral fracture | Injury, poisoning and procedural complications | MedDRA (12.0) | Systematic Assessment |
|
| Wrist fracture | Injury, poisoning and procedural complications | MedDRA (12.0) | Systematic Assessment |
|
| Alanine aminotransferase increased | Investigations | MedDRA (12.0) | Systematic Assessment |
|
| Aspartate aminotransferase increased | Investigations | MedDRA (12.0) | Systematic Assessment |
|
| Blood 1,25-dihydroxycholecalciferol decreased | Investigations | MedDRA (12.0) | Systematic Assessment |
|
| Blood creatinine increased | Investigations | MedDRA (12.0) | Systematic Assessment |
|
| Ejection fraction decreased | Investigations | MedDRA (12.0) | Systematic Assessment |
|
| Electrocardiogram ST-T change | Investigations | MedDRA (12.0) | Systematic Assessment |
|
| Hepatic enzyme increased | Investigations | MedDRA (12.0) | Systematic Assessment |
|
| Transaminases increased | Investigations | MedDRA (12.0) | Systematic Assessment |
|
| Urine albumin/creatinine ratio abnormal | Investigations | MedDRA (12.0) | Systematic Assessment |
|
| Urine albumin/creatinine ratio increased | Investigations | MedDRA (12.0) | Systematic Assessment |
|
| Urine output decreased | Investigations | MedDRA (12.0) | Systematic Assessment |
|
| Weight decreased | Investigations | MedDRA (12.0) | Systematic Assessment |
|
| Alkalosis | Metabolism and nutrition disorders | MedDRA (12.0) | Systematic Assessment |
|
| Anorexia | Metabolism and nutrition disorders | MedDRA (12.0) | Systematic Assessment |
|
| Carnitine deficiency | Metabolism and nutrition disorders | MedDRA (12.0) | Systematic Assessment |
|
| Copper deficiency | Metabolism and nutrition disorders | MedDRA (12.0) | Systematic Assessment |
|
| Decreased appetite | Metabolism and nutrition disorders | MedDRA (12.0) | Systematic Assessment |
|
| Dehydration | Metabolism and nutrition disorders | MedDRA (12.0) | Systematic Assessment |
|
| Hyperglycaemia | Metabolism and nutrition disorders | MedDRA (12.0) | Systematic Assessment |
|
| Hyperkalaemia | Metabolism and nutrition disorders | MedDRA (12.0) | Systematic Assessment |
|
| Hypocalcaemia | Metabolism and nutrition disorders | MedDRA (12.0) | Systematic Assessment |
|
| Hypoglycaemia | Metabolism and nutrition disorders | MedDRA (12.0) | Systematic Assessment |
|
| Hypokalaemia | Metabolism and nutrition disorders | MedDRA (12.0) | Systematic Assessment |
|
| Selenium deficiency | Metabolism and nutrition disorders | MedDRA (12.0) | Systematic Assessment |
|
| Vitamin A deficiency | Metabolism and nutrition disorders | MedDRA (12.0) | Systematic Assessment |
|
| Vitamin B complex deficiency | Metabolism and nutrition disorders | MedDRA (12.0) | Systematic Assessment |
|
| Vitamin B1 deficiency | Metabolism and nutrition disorders | MedDRA (12.0) | Systematic Assessment |
|
| Vitamin B12 deficiency | Metabolism and nutrition disorders | MedDRA (12.0) | Systematic Assessment |
|
| Vitamin B6 deficiency | Metabolism and nutrition disorders | MedDRA (12.0) | Systematic Assessment |
|
| Vitamin C deficiency | Metabolism and nutrition disorders | MedDRA (12.0) | Systematic Assessment |
|
| Vitamin D deficiency | Metabolism and nutrition disorders | MedDRA (12.0) | Systematic Assessment |
|
| Vitamin E deficiency | Metabolism and nutrition disorders | MedDRA (12.0) | Systematic Assessment |
|
| Zinc deficiency | Metabolism and nutrition disorders | MedDRA (12.0) | Systematic Assessment |
|
| Arthralgia | Musculoskeletal and connective tissue disorders | MedDRA (12.0) | Systematic Assessment |
|
| Back pain | Musculoskeletal and connective tissue disorders | MedDRA (12.0) | Systematic Assessment |
|
| Bone pain | Musculoskeletal and connective tissue disorders | MedDRA (12.0) | Systematic Assessment |
|
| Extremity contracture | Musculoskeletal and connective tissue disorders | MedDRA (12.0) | Systematic Assessment |
|
| Flank pain | Musculoskeletal and connective tissue disorders | MedDRA (12.0) | Systematic Assessment |
|
| Joint range of motion decreased | Musculoskeletal and connective tissue disorders | MedDRA (12.0) | Systematic Assessment |
|
| Myalgia | Musculoskeletal and connective tissue disorders | MedDRA (12.0) | Systematic Assessment |
|
| Neck pain | Musculoskeletal and connective tissue disorders | MedDRA (12.0) | Systematic Assessment |
|
| Osteopenia | Musculoskeletal and connective tissue disorders | MedDRA (12.0) | Systematic Assessment |
|
| Pain in extremity | Musculoskeletal and connective tissue disorders | MedDRA (12.0) | Systematic Assessment |
|
| Basal ganglion degeneration | Nervous system disorders | MedDRA (12.0) | Systematic Assessment |
|
| Dizziness | Nervous system disorders | MedDRA (12.0) | Systematic Assessment |
|
| Headache | Nervous system disorders | MedDRA (12.0) | Systematic Assessment |
|
| Hypoaesthesia | Nervous system disorders | MedDRA (12.0) | Systematic Assessment |
|
| Paraesthesia | Nervous system disorders | MedDRA (12.0) | Systematic Assessment |
|
| Insomnia | Psychiatric disorders | MedDRA (12.0) | Systematic Assessment |
|
| Chromaturia | Renal and urinary disorders | MedDRA (12.0) | Systematic Assessment |
|
| Dysuria | Renal and urinary disorders | MedDRA (12.0) | Systematic Assessment |
|
| Dysmenorrhoea | Reproductive system and breast disorders | MedDRA (12.0) | Systematic Assessment |
|
| Asthma | Respiratory, thoracic and mediastinal disorders | MedDRA (12.0) | Systematic Assessment |
|
| Cough | Respiratory, thoracic and mediastinal disorders | MedDRA (12.0) | Systematic Assessment |
|
| Dyspnoea | Respiratory, thoracic and mediastinal disorders | MedDRA (12.0) | Systematic Assessment |
|
| Nasal congestion | Respiratory, thoracic and mediastinal disorders | MedDRA (12.0) | Systematic Assessment |
|
| Pharyngolaryngeal pain | Respiratory, thoracic and mediastinal disorders | MedDRA (12.0) | Systematic Assessment |
|
| Postnasal drip | Respiratory, thoracic and mediastinal disorders | MedDRA (12.0) | Systematic Assessment |
|
| Respiratory tract congestion | Respiratory, thoracic and mediastinal disorders | MedDRA (12.0) | Systematic Assessment |
|
| Wheezing | Respiratory, thoracic and mediastinal disorders | MedDRA (12.0) | Systematic Assessment |
|
| Dermatitis contact | Skin and subcutaneous tissue disorders | MedDRA (12.0) | Systematic Assessment |
|
| Ingrown hair | Skin and subcutaneous tissue disorders | MedDRA (12.0) | Systematic Assessment |
|
| Rash | Skin and subcutaneous tissue disorders | MedDRA (12.0) | Systematic Assessment |
|
| Skin irritation | Skin and subcutaneous tissue disorders | MedDRA (12.0) | Systematic Assessment |
|
| Urticaria | Skin and subcutaneous tissue disorders | MedDRA (12.0) | Systematic Assessment |
|
| Wisdom teeth removal | Surgical and medical procedures | MedDRA (12.0) | Systematic Assessment |
|
| Hypertension | Vascular disorders | MedDRA (12.0) | Systematic Assessment |
|
| Hypotension | Vascular disorders | MedDRA (12.0) | Systematic Assessment |
|
Not provided
Not provided
| D006402 |
| Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D006453 | Hemoglobinopathies |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D019189 | Iron Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D001555 |
| Benzene Derivatives |
| D006841 | Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D014230 | Triazoles |
| D001393 | Azoles |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
|
| Week 25 Absolute Change from Baseline |
|
|
| Week 49 |
|
|
| Week 49 Absolute Change from Baseline |
|
|
| Week 77 |
|
|
| Week 77 Absolute Change from Baseline |
|
|
|
| Week 25 Absolute change from baseline |
|
|
| Week 49 |
|
|
| Week 49 Absolute change from baseline |
|
|
| Week 77 |
|
|
| Week 77 Absolute change from baseline |
|
|
|
| Week 25 Absolute change from baseline |
|
|
| Week 49 |
|
|
| Week 49 Absolute change from baseline |
|
|
| Week 77 |
|
|
| Week 77 Absolute change from baseline |
|
|